# Sitagliptin for implantation

Submission date 19/12/2016	<b>Recruitment status</b> No longer recruiting
Registration date 19/12/2016	<b>Overall study status</b> Completed
Last Edited 17/06/2020	<b>Condition category</b> Pregnancy and Childbirth

	1	Prospectiv	velv re	giste	red
_					

- [] Protocol
- [] Statistical analysis plan
- [X] Results
- [] Individual participant data

#### Plain English summary of protocol

Background and study aims

Miscarriage is defined as the loss of pregnancy before 24 weeks of pregnancy and is the most common complication of pregnancy. 15-25% of pregnancies end in miscarriage, and between 25 and 50% of women will experience at least one miscarriage. Around 1% of all women experience recurrent miscarriage, where they experience several miscarriages in a row. Currently, the only effective treatment to prevent miscarriage is heparin and aspirin for those women with antiphospholipid syndrome (APLS). APLS is a disorder of the immune system that causes an increased risk of blood clots, and occurs in around 15% of women who experience recurrent miscarriage. However, there is no effective treatment for the 85% of recurrent miscarriage patients who do not also suffer from APLS. This study is based on new evidence that has shown that there is a strong association between recurrent miscarriage and a deficiency in stem cells at the endometrium (lining of the womb). The aim of this study is to find out if taking a medication called Sitagliptin, which has been shown in animal studies to increase the number of stem cells in other areas of the body in response to injury, can help increase the number of stem cells in the endometrium.

Who can participate?

Women who have experienced recurrent miscarriage

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group receive 100mg Sitagliptin and those in the second group receive a placebo (dummy pill). At the start of the study and then after three months, the stem cell count in the endometrium is measured and the lining of the womb is assessed to see if it has become more favourable for successful implantation.

What are the possible benefits and risks of participating? Not provided at time of registration

Where is the study run from? East Surrey Hospital (UK)

When is the study starting and how long is it expected to run for? June 2016 to August 2017 Who is funding the study? National Institute of Academic Anaesthesia (UK)

Who is the main contact? Professor Siobhan Quenby simplant@uhcw.nhs.uk

### **Contact information**

**Type(s)** Scientific

**Contact name** Prof Siobhan Quenby

#### **Contact details**

University Hospitals Coventry and Warwickshire NHS Trust Clifford Bridge Road Walsgrave Coventry United Kingdom CV2 2DX +44 2476 964000 simplant@uhcw.nhs.uk

### Additional identifiers

**EudraCT/CTIS number** 2016-001120-54

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers 31796

### Study information

#### Scientific Title

Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?

#### Acronym SIMPLANT

#### Study objectives

The aim of this study is to assess whether Sitagliptin increases endometrial mesenchymal stem cells in women with repeated miscarriage compared to placebo.

**Ethics approval required** Old ethics approval format

**Ethics approval(s)** South Central - Hampshire B Research Ethics Committee, 14/06/2016, ref: 16/SC/0229

**Study design** Randomised; Interventional; Design type: Prevention, Drug, Cellular

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Hospital

**Study type(s)** Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Specialty: Reproductive health and childbirth, Primary sub-specialty: Maternal/ Fetal medicine; UKCRC code/ Disease: Reproductive Health and Childbirth/ Other disorders originating in the perinatal period, Reproductive Health and Childbirth/ Fetus and newborn affected by maternal factors and by complications of pregnancy, labour and deliver

#### Interventions

Participants are randomised to receive 100mg sitagliptin or placebo. Participants are followed up after three months.

Intervention Type Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Sitagliptin

#### Primary outcome measure

The number of colonies per thousand endometrial stromal cells after three months of the IMP determined by a clonogenic assay.

#### Secondary outcome measures

- 1. Change in the expression of DPP4 at the endometrium determined by immunohistochemistry
- 2. RNA sequencing
- 3. Methylation status of implantation related genes
- 4. Adverse events/serious adverse events
- 5. Acceptability of study determined by questionnaire
- 6. Follow up pregnancy rates and outcomes

#### Overall study start date

01/06/2016

#### **Completion date**

31/08/2017

## Eligibility

#### Key inclusion criteria

- 1. Provision of informed written consent
- 2. History of recurrent miscarriage 3 or more miscarriages (three or more spontaneous pregnancy losses prior to 24 weeks gestation)
- 3. Age 18-42 years at consent

4. Any BMI – no dose adjustment needed for BMI. BMI has no clinically meaningful effect on the pharmacokinetics of Sitagliptin.

- 5. Willing and able to give consent for the study and endometrial biopsy.
- 6. Ability to fully understand the requirements of the protocol

7. Adequate renal function , defined as Urea 2.5 – 7.8mmol/L, Creatinine 50 -90umol/L,

potassium 3.5 – 5.3mmol/L, Sodium 133 -146mmol/L

8. Adequate hepatic function, defined as total protein 60 – 80g/L, Albumin 35-50g/L, Bilirubin 4-20umol/L, Alkaline Phosphatase (ALP) 35-105U/L, Alanine Transferase (ALT) 5-38 U/L

9. Negative pregnancy test on the day of randomisation

Participant type(s) Patient

**Age group** Adult

**Lower age limit** 18 Years

**Upper age limit** 42 Years

**Sex** Female

#### Target number of participants

Planned Sample Size: 34; UK Sample Size: 34

Total final enrolment

#### Key exclusion criteria

1. Under 18 years of age – the safety and effectiveness of Sitagliptin in paediatric patients under 18 has not yet been established

2. Type I Diabetes – Sitagliptin should not be used in type 1 diabetes

3. Type II Diabetes – based on medical history

4. Pregnancy (tested at multiple points in trial)

5. Breast feeding – Caution is advised when prescribing Sitagliptin to breastfeeding mothers as it is not known if it is secreted in breast milk.

6. Known hypersensitivity to Sitagliptin

7. Not taking any medications with potential to react with interventional product:

7.1. Digoxin –plasma monitoring is needed if Sitagliptin used concomitantly in those at risk of digoxin toxicity

7.2. Enalapril – Sitagliptin appears to alter the hypotensive effects of enalapril

8. Previous diagnosis of pancreatitis

9. Renal impairment with eGFR<50 mL/min

10. Liver impairment, defined as any value out of normal range (total protein 60 – 80g/L, Albumin 35-50g/L, Bilirubin 4-20umol/L, Alkaline Phosphatase (ALP) 35-105U/L, Alanine Transferase (ALT) 5-38 U/L)

11. Inclusion in another intervention trial

12. Unwilling to use effective contraception for the duration of the trial (from consent)

13. Allergy/sensitivity to excipients of the IMP/placebo

Date of first enrolment

14/09/2016

Date of final enrolment 01/06/2017

### Locations

**Countries of recruitment** England

United Kingdom

#### Study participating centre

University Hospitals Coventry and Warwickshire NHS Trust

Clifford Bridge Road Walsgrave Coventry United Kingdom CV2 2DX

### Sponsor information

**Organisation** University Hospitals Coventry and Warwickshire NHS Trust

#### Sponsor details

Walsgrave General Hospital Clifford Bridge Road Coventry England United Kingdom CV2 2DX

**Sponsor type** Hospital/treatment centre

ROR https://ror.org/025n38288

### Funder(s)

Funder type Charity

**Funder Name** Tommy's Baby Charity

Alternative Name(s)

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Other non-profit organizations

**Location** United Kingdom

### **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date 31/08/2018

**IPD sharing plan summary** Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Basic results</u>			17/06/2020	No	No
HRA research summary			28/06/2023	No	No